Tularemia can present in several clinical forms — including ulceroglandular, pneumonic, and typhoidal disease. Across these presentations, evidence-based first-line management centres on antimicrobial therapy, with the choice of agent informed by patient-specific factors.
First-line management involves antimicrobial monotherapy. Multiple agents are recognised as appropriate first-line options; the full structured protocol defines which apply in a given clinical situation and details how they are used.
The key marker of treatment response is defervescence — resolution of fever. Clinical evidence indicates that fever typically resolves within approximately 4 days of initiating appropriate antimicrobial therapy.
Target: Defervescence within ~4 daysAll forms of tularemia, including ulceroglandular, pneumonic, and typhoidal disease, can be treated with ciprofloxacin, levofloxacin, gentamicin, or doxycycline.
Although defervescence occurred within 4 days of treatment, ciprofloxacin was discontinued in two (16.7%) children on days 3 and 7 of treatment because of development of a rash.
All five patients treated with levofloxacin monotherapy rapidly defervesced within 96 hours of treatment initiation and survived.
View source ↗